Tech Company Financing Transactions
Light Sciences Oncology Funding Round
Light Sciences Oncology closed a $30 million Series B funding round on 7/10/2007. Investors included private investors.
Transaction Overview
Company Name
Announced On
7/10/2007
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
Proceeds Purpose
LSO will use the funds to continue clinical development of Litx, including two ongoing pivotal Phase III clinical trials in patients with hepatocellular carcinoma (HCC), initiated in August 2006, and colorectal cancer metastatic to the liver (MCRC), initiated in July 2007. It will also use the funds to continue a Phase II trial of Litx in patients with brain cancer and to initiate a Phase I study in patients with benign prostatic hyperplasia (BPH).
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
12600 SE 38th St. 111
Bellevue, WA 98006
USA
Bellevue, WA 98006
USA
Phone
Website
Email Address
Overview
LSO is currently developing Litx for the treatment of patients with cancers such as hepatoma, metastatic colorectal cancer and glioma, for which the current therapeutic alternatives are of limited efficacy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Robert Littauer
VP - Regulatory Affairs
Lisa Koch-Hulle
Browse more venture capital transactions:
Prev: 7/10/2007: Cellumen venture capital transaction
Next: 7/11/2007: GlassHouse Technologies venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record all VC transactions involving tech companies. All VC database entries on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs